| ISIN | LU2041626032 |
|---|---|
| Valor Number | 49473298 |
| Bloomberg Global ID | |
| Fund Name | JSS Sustainable Equity - Future Health C CHF acc |
| Fund Provider |
J. Safra Sarasin Investmentfonds AG
Basel, Switzerland Phone: +41 58 317 44 44 Web: www.jsafrasarasin.com |
| Fund Provider | J. Safra Sarasin Investmentfonds AG |
| Representative in Switzerland |
J. Safra Sarasin Investmentfonds AG Basel Phone: +41 58 317 44 00 |
| Distributor(s) |
Bank J. Safra Sarasin AG Basel Phone: +41 58 317 44 00 |
| Asset Class | Equities |
| EFC Category | |
| Distribution Policy | Accumulation |
| Home Country | Luxembourg |
| Issuing Condition | The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel) |
| Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
| Investment Strategy *** | The investment objective of the fund is to achieve long-term capital growth. The Reference Currency of the Sub-Fund is the US Dollar (USD). The assets of the fund are mainly invested worldwide either directly (min. 67% of the SubFund’s assets) or indirectly in equity securities that offer an exposure to one or multiple emerging and transformational health trends. The Sub-Fund invests in leading companies and niche players whose products and services contribute to the improvement of health outcome and the dampening of rising healthcare costs. |
| Peculiarities |
| Current Price * | 98.02 CHF | 30.10.2025 |
|---|---|---|
| Previous Price * | 97.54 CHF | 29.10.2025 |
| 52 Week High * | 105.30 CHF | 30.01.2025 |
| 52 Week Low * | 85.52 CHF | 11.04.2025 |
| NAV * | 98.02 CHF | 30.10.2025 |
| Issue Price * | ||
| Redemption Price * | ||
| Closing Price * | ||
| Indicative Minimum Price | ||
| Fund Assets *** | 107,709,287 | |
| Unit/Share Assets *** | 9,908,126 | |
| Trading Information SIX | ||
| YTD Performance | -0.77% |
31.12.2024 - 30.10.2025
31.12.2024 30.10.2025 |
|---|---|---|
| 1 month | +6.31% |
30.09.2025 - 30.10.2025
30.09.2025 30.10.2025 |
| 3 months | +9.57% |
30.07.2025 - 30.10.2025
30.07.2025 30.10.2025 |
| 6 months | +5.15% |
30.04.2025 - 30.10.2025
30.04.2025 30.10.2025 |
| 1 year | -2.60% |
30.10.2024 - 30.10.2025
30.10.2024 30.10.2025 |
| 2 years | +15.64% |
30.10.2023 - 30.10.2025
30.10.2023 30.10.2025 |
| 3 years | -13.41% |
31.10.2022 - 30.10.2025
31.10.2022 30.10.2025 |
| 5 years | -6.90% |
30.10.2020 - 30.10.2025
30.10.2020 30.10.2025 |
| Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI Date | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Johnson & Johnson | 8.00% | |
|---|---|---|
| Eli Lilly and Co | 7.24% | |
| Danaher Corp | 6.45% | |
| Sanofi SA | 6.21% | |
| argenx SE | 5.71% | |
| Boston Scientific Corp | 4.87% | |
| AbbVie Inc | 4.65% | |
| Fresenius SE & Co KGaA | 4.63% | |
| Merck & Co Inc | 4.63% | |
| Lonza Group Ltd | 4.45% | |
| Last data update | 30.09.2025 | |
| TER | 1.38% |
|---|---|
| TER date | 30.04.2025 |
| Performance Fee *** | |
| PTR | |
| Max. Management Fee *** | 1.50% |
| Ongoing Charges *** | 1.38% |
|
SRRI ***
|
|
| SRRI date *** | 30.09.2025 |